TICKERNERD
Menu
NVCTNVCTHealthcare · Biotechnology

NVCT Stock Forecast: Nuvectis Pharma, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$19
−1.40% on the day

The 5 Wall Street analysts covering Nuvectis Pharma, Inc. hold a median 12-month price target of $34 — +79.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$617.7M
Ticker Nerd rank
68 / 100
Median analyst target
$34
Analysts covering
5
Total return, dividends reinvested
1W
+0.1%
1M
+3.7%
YTD
+151.1%
1Y
+194.9%
From 52W high
−33.5%
From 52W low
+235.6%
$6
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVCT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nuvectis Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
89
Volatility
85
Momentum
78
Accruals
78
Revisions
63
Size
52
Issuance
38
Growth
29
Quality
28

Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Quality (28): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVCT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVCT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26NVCTHigh $39Median $34Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $30Median $34High $39

The green dot is the last close — the median target sits +79.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 July 2026Roth CapitalMaintainsBuy$20 → $33
22 June 2026HC Wainwright & Co.MaintainsBuy—
12 June 2026HC Wainwright & Co.MaintainsBuy—
4 Aug 2025HC Wainwright & Co.MaintainsBuy—
30 Apr 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025Maxim GroupInitiatesBuy—
17 Mar 2025Laidlaw & Co.InitiatesBuy—
25 Feb 2025HC Wainwright & Co.MaintainsBuy—
6 Aug 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
15 Sept 2023HC Wainwright & Co.ReiteratesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy—
10 Feb 2023HC Wainwright & Co.ReiteratesBuy—
13 July 2022Ladenburg ThalmannInitiatesBuy—
10 May 2022HC Wainwright & Co.MaintainsBuy—
2 Mar 2022HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVCT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NVCT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Nuvectis Pharma, Inc. (NVCT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.4×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
55.8×

Cheaper than 2% of US stocks

EV / EBITDA
−21.6×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−214.6%

Higher than 6% of US stocks

Return on assets
−73.1%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NVCT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NVCTNuvectis Pharma, Inc.$617.7M
68
EIKNEikon Therapeutics, Inc.$597.8M
2
CRMDCorMedix, Inc.$590.7M
59
VSTMVerastem, Inc.$578.0M
56
ARVNArvinas, Inc.$576.1M
84
FDMT4D Molecular Therapeutics, Inc.$621.8M
54
ALTAltimmune, Inc.$571.4M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nuvectis Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVCT news & analysis

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

GlobeNewsWire · 4 Aug 2026neutral

Nuvectis Pharma, a clinical-stage biopharmaceutical company developing therapies for complement-related conditions and oncology, reported its financial results for the second quarter of 2026 and provided an update on recent business progress. The announcement was made via press release on August 4, 2026.

Why it matters — A quarterly financial and business update provides NVCT watchers with the company's latest operational and financial status.

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

Zacks Investment Research · 29 July 2026positive

The mean of analysts' price targets for Nuvectis Pharma points to a 56.4% upside in the stock. Strong agreement among analysts in raising earnings estimates suggests an upside for the stock.

Why it matters — NVCT watchers would care because analyst price targets and upward earnings estimate revisions can signal positive expectations for the stock.

FAQ

Frequently asked questions about NVCT stock

What is the NVCT stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Nuvectis Pharma, Inc. have a median 12-month price target of $34, with estimates ranging from $30 to $39. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVCT stock a buy right now?

Of the 5 analysts covering Nuvectis Pharma, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuvectis Pharma, Inc. 68 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVCT?

As at 15 Aug 2026, Nuvectis Pharma, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).

Will NVCT stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +79.3% from the last close, and Ticker Nerd's factor model ranks Nuvectis Pharma, Inc. 68 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVCT stock forecast for 2030?

No analyst covering Nuvectis Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $39 over the next 12 months.

How has NVCT stock performed over the past year?

Nuvectis Pharma, Inc. returned +194.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nuvectis Pharma, Inc. do?

Nuvectis Pharma Inc. is a biopharmaceutical company engaged in the development and commercialization of innovative cancer treatments.

What is the latest news on NVCT?

The most recent item we track (GlobeNewsWire, 4 Aug 2026): "Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights". Nuvectis Pharma, a clinical-stage biopharmaceutical company developing therapies for complement-related conditions and oncology, reported its financial results for the second quarter of 2026 and provided an update on recent business progress. The announcement was made via press release on August 4, 2026.

Company

About Nuvectis Pharma, Inc.

Nuvectis Pharma Inc. is a biopharmaceutical company engaged in the development and commercialization of innovative cancer treatments. Its primary function is to explore novel therapies that address significant unmet medical needs in oncology. The company focuses on advancing proprietary compounds through clinical trials, aiming to transform the therapeutic landscape for cancer patients. Nuvectis is deeply involved in pioneering research, leveraging cutting-edge technology and strategic collaborations with research institutions. Its work impacts sectors within healthcare and pharmaceuticals, particularly those devoted to oncology and biopharmaceutical innovation. By contributing to the pipeline of potential cancer therapies, Nuvectis Pharma Inc. plays a crucial role in the drug development process, attracting interest from both scientific communities and investors seeking advancements in health-related technologies. Its efforts highlight the importance of supportive frameworks for novel drug development and underscore the complex landscape of modern oncology treatment research.

CEO Mr. Ron Bentsur M.B.A. · 16 employees · United States · https://www.nuvectis.com